AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. INTC
2. SPCX
3. DSX
4. GNK
5. DAL
6. AWK
7. MDA
8. ACN
9. III
10. SAN

Go back to AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
AbbVie (NYSE: ABBV) Delayed: 216.49 -4.74 (2.14%)
Previous Close $221.23    52 Week High $68.12 
Open $221.37    52 Week Low $50.71 
Day High $222.35    P/E 46.96 
Day Low $215.37    EPS $4.61 
Volume 9,646,087